This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Geron Corporation. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Dinesh Gala: Innovator in Telomerase Inhibition
Introduction
Dinesh Gala is a notable inventor based in Beerse, Belgium. He has made significant contributions to the field of biochemistry, particularly in the development of telomerase inhibitors. With a total of 2 patents to his name, Gala's work is paving the way for advancements in cancer treatment.
Latest Patents
One of Gala's latest patents is focused on a process for preparing the telomerase inhibitor imetelstat. This invention involves a three-step per cycle solid-phase support bound process. The steps include deprotection of the 3′-amino group of the support-bound oligonucleotide, coupling with a 5′-phosphoramidite, and sulfurization with an acyl disulfide. Notably, this process is characterized by the absence of an additional capping step in each cycle, which is typically used to prevent unreacted 3′-amino oligonucleotide groups from reacting during subsequent cycles.
Career Highlights
Dinesh Gala is currently employed at Geron Corporation, where he continues to innovate in the field of biotechnology. His work is instrumental in the development of therapies that target telomerase, a key enzyme involved in cellular aging and cancer.
Collaborations
Gala collaborates with talented professionals in his field, including Jennifer Elizabeth Albaneze-Walker and Jale Muslehiddinoglu. These collaborations enhance the research and development efforts at Geron Corporation.
Conclusion
Dinesh Gala's contributions to the field of telomerase inhibition through his innovative patents are significant. His work at Geron Corporation and collaborations with esteemed colleagues further highlight his impact on biotechnology and cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
